Piqray: What EU Regulators Saw And What They Wanted
The European public assessment report for Novartis's advanced breast cancer therapy, Piqray (alpelisib), includes some interesting insights into what EU regulators are looking for in drug company clinical trials.
You may also be interested in...
As Vas Narasimhan spoke about his worries of missed diagnoses and worse outcomes, Q1 sales at the Swiss major's cancer business remained flat as new patient starts, physician visits and cancer screenings declined due to COVID-19.
Not everyone reviewing Daiichi Sankyo’s EU marketing application for Turalio agreed that the potential tenosynovial giant cell tumor treatment shouldn't be approved.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.